Get the Stockscreener App
46.84
0.47%
-0.235
Praxis Precision Medicines Inc stock is traded at $46.84, with a volume of 549.37K.
It is down -0.47% in the last 24 hours and down -12.98% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$47.08
Open:
$47.16
24h Volume:
549.37K
Relative Volume:
1.39
Market Cap:
$986.21M
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-5.1085
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+4.25%
1M Performance:
-12.98%
6M Performance:
-40.42%
1Y Performance:
-11.33%
1-Day Range:
$46.53
$48.67
1-Week Range:
$44.28
$49.97
52-Week Range:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
46.86 | 990.84M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.81 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.70 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.00 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.12 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.26 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines Inc. stock momentum explainedWeekly Earnings Recap & Low Risk Investment Opportunities - Newser
Advanced analytics toolkit walkthrough for Praxis Precision Medicines Inc.July 2025 Short Interest & Weekly Top Gainers Alerts - Newser
Protect Your Investment: Contact Levi & Korsinsky About the Praxis Precision Medicines, Inc. (PRAX) Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Praxis Precision Medicines, Inc. (PRAX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
What makes Praxis Precision Medicines Inc. stock price move sharplyQuarterly Profit Report & Real-Time Buy Signal Notifications - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - GlobeNewswire Inc.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaPortfolio Growth Summary & Consistent Return Investment Signals - Newser
How to monitor Praxis Precision Medicines Inc. with trend dashboardsGlobal Markets & Weekly Return Optimization Alerts - Newser
Should you hold or exit Praxis Precision Medicines Inc. nowJuly 2025 Final Week & Safe Entry Trade Signal Reports - Newser
Lost Money on Praxis Precision Medicines, Inc. (PRAX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Applying sector rotation models to Praxis Precision Medicines Inc.Market Performance Report & Verified Momentum Watchlists - Newser
Praxis Precision Medicines: Navigating Clinical Setbacks and the Biotech Investment Tightrope - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - PR Newswire
Can Praxis Precision Medicines Inc. rally from current levelsMarket Risk Analysis & Consistent Return Strategy Ideas - Newser
How Praxis Precision Medicines Inc. stock performs during market volatility2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
What indicators show strength in Praxis Precision Medicines Inc.2025 Volume Leaders & Weekly Return Optimization Alerts - Newser
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
Is Praxis Precision Medicines Inc. stock reversal real or fake2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Did Praxis Precision Medicines, Inc. (PRAX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Reversal indicators forming on Praxis Precision Medicines Inc. stockStop Loss & Accurate Entry/Exit Alerts - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Praxis Precision Medicines, Inc. (PRAX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Praxis Precision Medicines, Inc. (PRAX) And Encourages Investors to Reach Out - ACCESS Newswire
Praxis Precision Medicines shares fall 1.89% intraday after Schall Law Firm investigates claims of false statements. - AInvest
Levi & Korsinsky Investigates Possible Securities Fraud by Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - Barchart.com
Will Praxis Precision Medicines Inc. bounce back from current supportGap Up & Safe Capital Allocation Plans - Newser
Does Praxis Precision Medicines Inc. stock pay reliable dividends2025 Buyback Activity & Precise Buy Zone Tips - Newser
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
What are the future prospects of Praxis Precision Medicines Inc.Volume Surge With Low Float - thegnnews.com
Will Praxis Precision Medicines Inc. see short term momentumRisk-Managed Trade Alerts for Consistency - Newser
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock By Investing.com - Investing.com South Africa
Chardan Capital Brokers Lower Earnings Estimates for PRAX - Defense World
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Tuesday - Defense World
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.14%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):